Are ENLV insiders buying or selling?

In the last 90 days, Enlivex (ENLV) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own ENLV?

See every hedge fund and asset manager holding Enlivex (ENLV).

How much of ENLV trades in dark pools?

Track Enlivex (ENLV) dark pool activity and off-exchange block trades.

Enlivex (ENLV) — 45.4% Short — Squeeze Watch

Also trades as: ENLV.TA (TLV) · $vol 0M

$2.24

-2.02 (-47.42%)

Weekly Expected Move ±10.2%

$3 $4 $4 $5 $5

NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 32 · $37.7M mcap · 17M float · 0.252% daily turnover · Short 45% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

Smart Money Score

Watch 25

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$37.7M

52W Range2.08-31.5

Volume4,010,853

Avg Volume42,224

Beta1.52

Dividend—

Analyst Ratings

3 Buy 1 Hold 0 Sell

Consensus Buy

Company Info

CEOOren Hershkovitz

Employees34

SectorHealthcare

IndustryBiotechnology

IPO Date2014-07-31

Websiteenlivex.com

14 Einstein Street
Ness Ziona, TA 7403618
IL

972 8 662 3301

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Latest News

Enlivex plunges in pre-market trade after announcing $400M private placement

Bearish SeekingAlpha · 13h ago

Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why

Bullish Zacks · 2w ago